|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?显示文摘Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC. | Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini | 2018 | World Journal of Gastroenterology2018，24，36： | 14 |
| 2 | Interespecific variation in the composition of volatile oils from the leaves of Swietenia macrophylla king (Meliaceae)显示文摘 | Marisi GS | 2010 | Quire Nova2010，33，5： | 1 |
| 3 | Electrophysio- logical responses of female and male Hypsipyla grandel- la to Swietenia macrophylla essential oils显示文摘 | Marisi GS Lueiane G Batista Pereira | 2003 | J Chem Ecol2003，29，9： | 1 |
| 4 | Eleetrophysiological responses of female and male Hypsipyla grandella (Zeller) to Swietenia macrophylla es- sential oils显示文摘 | MARISIS G S | 2003 | J Chem Ecol2003，29，9： | 1 |
| 5 | A note on the heritability of memory span显示文摘 | Arthur R. Jensen Daniel Q. Marisi | 1979 | Behavior Genetics1979，，5： | 1 |
| 6 | Donepezil: An Important Prototype to the Design of New Drug Candidates for Alzheimerμs Disease显示文摘 | Maria Cecilia Rodrigues Simoes Flavia Pereira Dias Viegas Marcella Soares Moreira Matheus de Freitas Silva Mariana Maximo Riquiel Patricia Mattos da Rosa Maísa Rosa Castelli Marcelo Henrique dos Santos Marisi Gomes Soares Claudio Viegas | 2014 | Mini-Reviews in Medicinal Chemistry2014，，1： | 1 |
| 7 | A test of multidimensional anxiety theory with male wheelchair basketball players显示文摘 | Perreault S Marisi DQ | | 0，，： | 1 |
| 8 | The effects of related and unrelated stress on motor performance 显示文摘 | Marisi D Q Anshel M H | 1976 | New Zealand Journal of Health Physical Education and Recreation1976，9，： | 1 |
| 9 | Polymorphism AGT2(rs4762)is involved in the development of dermatologic events:Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib显示文摘BACKGROUND Dermatologic adverse events(DAEs)are associated with a better outcome in patients with hepatocellular carcinoma(HCC)irrespective of the therapeutic agent received.The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors(TKIs)to the skin or an immune-mediated reaction triggered by the oncologic treatment.As is the case in other conditions,individual genetic variants may partially explain a higher risk of DAEs.AIM To evaluate the contribution of several gene variants to the risk of developing DAEs in HCC patients treated with TKIs.METHODS We first analyzed 27 single-nucleotide polymorphisms(SNPs)from 12 genes selected as potential predictors of adverse event(AE)development in HCC patients treated with sorafenib[Barcelona Clinic Liver Cancer 1(BCLC1)cohort].Three additional cohorts were analyzed for AGT1(rs699)and AGT2(rs4762)polymorphisms-initially identified as predictors of DAEs:BCLC2(n=79),Northern Italy(n=221)and Naples(n=69)cohorts,respectively.The relation between SNPs and DAEs and death were assessed by univariate and multivariate Cox regression models,and presented with hazard ratios and their 95%confidence intervals(95%CI).RESULTS The BCLC1 cohort showed that patients with arterial hypertension(AHT)(HR=1.61;P value=0.007)and/or AGT SNPs had an increased risk of DAEs.Thereafter,AGT2(rs4762)AA genotype was found to be linked to a statistically significant increased probability of DAEs(HR=5.97;P value=0.0201,AA vs GG)in the Northern Italy cohort by multivariate analysis adjusted for BCLC stage,ECOG-PS,diabetes and AHT.The value of this genetic marker was externally validated in the cohort combining the BCLC1,BCLC2 and Naples cohorts[HR=3.12(95%CI:1.2-8.14),P value=0.0199,AGT2(rs4762)AA vs AG genotype and HR=2.73(95%CI:1.18-6.32)P value=0.0188,AGT2(rs4762)AA vs GG genotype].None of the other gene variants tested were found to be associated with the risk of DAE development.CONCLUSION DAE development in HCC patients receiving TKIs could be explained by the AGT2(rs4762)gene variant.If validated in other anti-oncogenic treatments,it might be considered a good prognosis marker. | Víctor Sapena Massimo Iavarone Loreto Boix Floriana Facchetti Maria Guarino Marco Sanduzzi Zamparelli Alessandro Granito Esther Samper Mario Scartozzi Josep Corominas Giorgia Marisi Alba Díaz Andrea Casadei-Gardini Laura Gramantieri Pietro Lampertico Filomena Morisco Ferran Torres Jordi Bruix María Reig | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员